Charles River Laboratories Provides Access to Relevant, Well-Characterized Pediatric PDX Collection for Oncology Research
16 Outubro 2023 - 9:00AM
Business Wire
Recently established regulatory guidelines make
testing for pediatric indications a necessary step in oncology
research and development
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced the ability to conduct preclinical cancer research using
ITCC-P4’s well-characterized collection of 400 annotated pediatric
cancer models. As a global partner, Charles River is offering
clients access to this collection. These are critical models for
research, as the U.S. Food and Drug Administration’s (FDA) Research
to Accelerate Cures and Equity (RACE) for Children Act, requires
all oncology drugs to be tested for pediatric indications ahead of
approval. Additionally, the EU regulation of the European Medicines
Agency (EMA) is being adapted to mirror the FDA’s regulations.
“Globally, 400,000 children and adolescents develop cancer each
year, and approximately one in four cannot be cured with currently
available therapies,” said Aidan Synnott, Corporate Vice President,
Global Discovery Services at Charles River. “The ITCC-P4 collection
is comprehensive, relevant, and well-characterized, meaning we can
better assess the safety and efficacy of new oncology treatments
specifically for children. This will ultimately lead to new
treatment options for a critically important patient
population.”
The ITCC-P4 repertoire offers access to models that are relevant
to pediatric cancer, allowing researchers to appropriately
investigate targets of interest, and ultimately increasing
translation to preclinical trials. Pediatric tumors have different
genomic drivers and phenotypes than adult tumors, requiring unique
preclinical models. The ITCC-P4 collection is supported by an
accompanying dataset consisting of molecular phenotyping and
pharmacological characterization backed-up by expertise from
internationally recognized pediatricians. By offering this
collection, Charles River is combining decades of oncology research
experience with a powerful tool that will better guide critical
investigative decisions.
“Charles River worked on 84 percent of the FDA-approved cancer
therapies over the last five years, and has delivered 16 oncology
candidates to our partners,” added Julia Schüler, DVM, PhD,
Research Director and Therapeutic Area Lead, Oncology at Charles
River. “We are uniquely positioned to help researchers navigate
through these new guidelines and progress their studies.”
Charles River offers a comprehensive portfolio of oncology drug
discovery and development services, from model selection to safety
assessment and support for biologic therapies. With a global
infrastructure and deep scientific bench, Charles River is
positioned to support programs from basic science to IND
submission.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231016278105/en/
Charles River Investor Contact: Todd Spencer Corporate
Vice President, Investor Relations +1- 781-222-6455
todd.spencer@crl.com Charles River Media Contact: Amy
Cianciaruso Corporate Vice President & Chief Communications
Officer +1-781-222-6168 amy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Charles River Laboratories (NYSE:CRL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024